Akademik Veri Yönetim Sistemi
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, cilt.9, sa.3, ss.152-157, 2008 (ESCI)
Objective: The aim of the study was to determine the outcomes of neoadjuvant chemotherapy and its predicting factors in patients with stage IB2 cervical cancer. Materials and Methods: The data of 36 patients with stage IB2 cervix carcinoma who received neoadjuvant chemotherapy (NACT) were retrospectively reviewed. Chemotherapy protocols were cisplatin/5-fluorauracil, cisplatin/UFT and carboplatin/ paclitaxel. After NACT, the patients were re-examined and the patients who had a tumor size less than 40 mm were operated (type III radical hysterectomy) and radiotherapy was given to the others. Results: The mean age of patients was 46.3 years and the mean follow up was 46.5 months. The mean tumor size was 51.4 mm before NACT and 32.7 mm after NACT. While 12 patients (33.3%) had an overall clinical response, complete clinical response was seen in four (11.1%), stabile disease was achieved in 22 (61.1%) and progression was seen in two (5.6%). Clinical response was affected by age (<= 45 vs >45). Tumor size before treatment, histopathology, chemotherapy protocol and the number of chemotherapy course did not have an effect on the observed responses. Discussion: In this study, the success of NACT was noted to be affected by age. Identification of the factors which determine the outcome of this treatment modality improves the effectiveness of NACT.